64% OWNED SUBSIDIARY
Cynaptec Pharmaceuticals
Cynaptec Pharmaceuticals is advancing L-130 (Psilocin Mucate), a novel conjugated psilocin compound, for the treatment of chronic cluster headache—one of the most painful and underserved neurological conditions.
The company focuses on developing next-generation psychedelic-derived therapeutics with improved pharmacokinetic profiles and reduced side effects.
SUBSIDIARY
Applied Lipid Technologies
Applied Lipid Technologies (ALT) is creating safe and cost-effective solutions to diseases involving cell membranes. The company is developing S-100, a unique lipid-based therapeutic candidate to treat adult sufferers with sickle cell disease.
ALT also markets Altemia®, a medical food brand for nutritional support in sickle cell disease management.
Focused on What We Do Best
Lobe Sciences is a pharmaceutical development company focused on identifying, advancing, and de-risking high-value drug candidates for rare and underserved medical conditions.